回复。

Reply.

机构信息

Department of Endocrinology, First Affiliated Hospital, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei, China.

出版信息

Hepatology. 2019 May;69(5):2304-2305. doi: 10.1002/hep.30553.

DOI:10.1002/hep.30553

PMID:30729549

Abstract

We sincerely thank Dr. Sikarin Upala for his interest in our article and for sharing his experience in the treatment of nonalcoholic fatty liver disease (NAFLD). NAFLD is prevalent in patients with type 2 diabetes mellitus (T2DM), yet only preliminary evidence are available on the effect of anti-diabetic agents to NAFLD in T2DM patients. According to clinical practice guidelines for NAFLD management , no pharmacotherapies are approved for the treatment of NAFLD. There is neither proper therapy for patients with T2DM and NAFLD. So we designed this 26-week comparative trial, aiming to evaluate the efficacy and safety of liraglutide, sitagliptin, and insulin glargine as an add-on treatment to metformin in patients with T2DM and NAFLD. This article is protected by copyright. All rights reserved.

摘要

我们衷心感谢 Sikarin Upala 博士对我们文章的关注，并分享他在治疗非酒精性脂肪性肝病（NAFLD）方面的经验。NAFLD 在 2 型糖尿病患者中很常见，但关于抗糖尿病药物对 T2DM 患者 NAFLD 的影响，仅有初步证据。根据 NAFLD 管理临床实践指南，尚无批准的药物可用于治疗 NAFLD。对于 T2DM 合并 NAFLD 的患者也没有合适的治疗方法。因此，我们设计了这项为期 26 周的对照试验，旨在评估利拉鲁肽、西他列汀和甘精胰岛素作为二甲双胍的附加治疗在 T2DM 和 NAFLD 患者中的疗效和安全性。本文受版权保护。版权所有。